search
Back to results

Study of Defibrillation Testing In Patients Undergoing Initial ICD Implantation (TNT-ICD)

Primary Purpose

Ventricular Arrhythmias

Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Defibrillation testing
Sponsored by
The Cooper Health System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ventricular Arrhythmias focused on measuring Implantable cardioverter defibrillator, Defibrillation threshold testing

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Initial ICD implantation (single, dual, or CRT) for a standard Class I or Class II indication according to the ACC/AHA/HRS practice guidelines
  • Anticipated life expectancy >6 months

Exclusion Criteria:

  • Contraindications to defibrillation testing as determined by the managing physician*
  • ICD replacement implants
  • Right-sided pectoral implants
  • Abdominal implants
  • Chronic oral amiodarone therapy (for >6 weeks and continued need for amiodarone)
  • Inability to give informed consent

    • Contraindications to defibrillation testing include the following: hemodynamic instability, LA thrombus, atrial fibrillation without adequate anticoagulation, LV thrombus, recent CVA or TIA, severe unrevascularized coronary artery disease or unstable angina, severe aortic stenosis, inotropic dependence, patient refusal, other patient-specific medical conditions that are deemed as contraindications, as determined by the implanting physician.

Sites / Locations

  • Cooper University HospitalRecruiting
  • University of Washington

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Defibrillation testing

No defibrillation testing

Arm Description

Defibrillation testing at initial ICD implantation

No defibrillation testing at initial ICD implantation

Outcomes

Primary Outcome Measures

Composite all-cause mortality and operative complications
The composite endpoint of implant complications and mortality rates will be compared in the DFT vs. no DFT groups.

Secondary Outcome Measures

1st shock efficacy for clinical occurrence of ventricular tachycardia (VT)/VF
The efficacy of 1st shock therapy for VT/VF will be compared between the DFT and no DFT groups.

Full Information

First Posted
February 24, 2012
Last Updated
July 17, 2013
Sponsor
The Cooper Health System
Collaborators
Medtronic, University of Washington
search

1. Study Identification

Unique Protocol Identification Number
NCT01905007
Brief Title
Study of Defibrillation Testing In Patients Undergoing Initial ICD Implantation
Acronym
TNT-ICD
Official Title
"Test-No Test" Implantable Cardioverter Defibrillator Pilot Study (TNT-ICD)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Unknown status
Study Start Date
December 2010 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Cooper Health System
Collaborators
Medtronic, University of Washington

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of this study is to compare the composite outcome of total mortality and operative complications in patients who do not undergo defibrillation testing to those who do undergo defibrillation testing at the time of initial ICD implantation.
Detailed Description
Implantable cardioverter-defibrillators (ICDs) are the most effective treatment for the primary and secondary prevention of sudden cardiac death (SCD). At the time of ICD implantation, ventricular fibrillation (VF) is typically induced to demonstrate effective arrhythmia termination by the implanted device. Although defibrillation threshold (DFT) testing with induction of VF at time of ICD insertion is currently considered the "standard of care," and instructions for usage of devices approved by the Food and Drug Administration (FDA) include labeling with DFT testing, the value of defibrillation testing with modern-day devices has been questioned. Defibrillation testing can be associated with serious complications and may add to the cost of the procedure. It is hypothesized that patients who do not undergo defibrillation testing will have outcomes similar to those who do undergo defibrillation testing at the time of initial implantation. This pilot study is being performed to determine the feasibility of performing a larger, multi-center clinical trial with longer follow-up to investigate whether or not defibrillation testing will have any impact on overall mortality, implant complications, or long-term first shock efficacy during clinical follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventricular Arrhythmias
Keywords
Implantable cardioverter defibrillator, Defibrillation threshold testing

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Defibrillation testing
Arm Type
Active Comparator
Arm Description
Defibrillation testing at initial ICD implantation
Arm Title
No defibrillation testing
Arm Type
No Intervention
Arm Description
No defibrillation testing at initial ICD implantation
Intervention Type
Device
Intervention Name(s)
Defibrillation testing
Other Intervention Name(s)
Medtronic implantable cardioverter defibrillator
Intervention Description
Defibrillation testing at initial ICD implantation
Primary Outcome Measure Information:
Title
Composite all-cause mortality and operative complications
Description
The composite endpoint of implant complications and mortality rates will be compared in the DFT vs. no DFT groups.
Time Frame
Procedure-related complications will be defined as those occurring within 90 days post-implantation and mortality will be measured at 2 year follow-up
Secondary Outcome Measure Information:
Title
1st shock efficacy for clinical occurrence of ventricular tachycardia (VT)/VF
Description
The efficacy of 1st shock therapy for VT/VF will be compared between the DFT and no DFT groups.
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Initial ICD implantation (single, dual, or CRT) for a standard Class I or Class II indication according to the ACC/AHA/HRS practice guidelines Anticipated life expectancy >6 months Exclusion Criteria: Contraindications to defibrillation testing as determined by the managing physician* ICD replacement implants Right-sided pectoral implants Abdominal implants Chronic oral amiodarone therapy (for >6 weeks and continued need for amiodarone) Inability to give informed consent Contraindications to defibrillation testing include the following: hemodynamic instability, LA thrombus, atrial fibrillation without adequate anticoagulation, LV thrombus, recent CVA or TIA, severe unrevascularized coronary artery disease or unstable angina, severe aortic stenosis, inotropic dependence, patient refusal, other patient-specific medical conditions that are deemed as contraindications, as determined by the implanting physician.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea M. Russo, MD
Phone
856-968-7096
Email
russo-andrea@cooperhealth.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Julie Field
Phone
856-669-8847
Email
field-julie@cooperhealth.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea M. Russo, MD
Organizational Affiliation
The Cooper Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cooper University Hospital
City
Camden
State/Province
New Jersey
ZIP/Postal Code
08103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea M. Russo, M.D.
Phone
856-968-7096
First Name & Middle Initial & Last Name & Degree
Julie Field
Phone
856-669-8847
Email
Field-Julie@cooperhealth.edu
First Name & Middle Initial & Last Name & Degree
Andrea M. Russo, MD
First Name & Middle Initial & Last Name & Degree
John Andriulli, MD
First Name & Middle Initial & Last Name & Degree
Matthew Ortman, MD
First Name & Middle Initial & Last Name & Degree
Claudine Pasquarello, PA-C
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeanne Poole, MD
First Name & Middle Initial & Last Name & Degree
Jeanne Poole, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
15840466
Citation
Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, Dixit S, Verdino RJ, Nayak HM, Callans DJ, Patel V, Marchlinski FE. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm. 2005 May;2(5):456-61. doi: 10.1016/j.hrthm.2005.01.015.
Results Reference
background
PubMed Identifier
17461879
Citation
Swerdlow CD, Russo AM, Degroot PJ. The dilemma of ICD implant testing. Pacing Clin Electrophysiol. 2007 May;30(5):675-700. doi: 10.1111/j.1540-8159.2007.00730.x.
Results Reference
background
PubMed Identifier
16945792
Citation
Mainigi SK, Cooper JM, Russo AM, Nayak HM, Lin D, Dixit S, Gerstenfeld EP, Hsia HH, Callans DJ, Marchlinski FE, Verdino RJ. Elevated defibrillation thresholds in patients undergoing biventricular defibrillator implantation: incidence and predictors. Heart Rhythm. 2006 Sep;3(9):1010-6. doi: 10.1016/j.hrthm.2006.05.028. Epub 2006 Jun 15.
Results Reference
background
PubMed Identifier
18687249
Citation
Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Anderson J, Chung K, Wong WS, Mark DB, Lee KL, Bardy GH; SCD-HeFT Investigators. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol. 2008 Aug 12;52(7):551-6. doi: 10.1016/j.jacc.2008.04.051.
Results Reference
background
PubMed Identifier
18243813
Citation
Birnie D, Tung S, Simpson C, Crystal E, Exner D, Ayala Paredes FA, Krahn A, Parkash R, Khaykin Y, Philippon F, Guerra P, Kimber S, Cameron D, Healey JS. Complications associated with defibrillation threshold testing: the Canadian experience. Heart Rhythm. 2008 Mar;5(3):387-90. doi: 10.1016/j.hrthm.2007.11.018. Epub 2007 Nov 28.
Results Reference
background
PubMed Identifier
16533250
Citation
Pires LA, Johnson KM. Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough? J Cardiovasc Electrophysiol. 2006 Feb;17(2):140-5. doi: 10.1111/j.1540-8167.2005.00294.x.
Results Reference
background

Learn more about this trial

Study of Defibrillation Testing In Patients Undergoing Initial ICD Implantation

We'll reach out to this number within 24 hrs